PIONEERING A NEW CLASS OF THERAPEUTIC ANTIBODIES

Our mission is to improve the treatment of cancer by creating and developing novel IgM and IgA antibodies.

antibody-solo

IGM Biosciences Appoints M. Kathleen Behrens, Ph.D., to Board of Directors

Dr. Kathy Behrens brings 35 years of biotech and investment industry experience and leadership IGM...
Read More...

IGM Biosciences Appoints Misbah Tahir as Chief Financial Officer

Mr. Tahir Brings More Than 20 Years of Financial and Strategic Planning Experience  IGM Biosciences,...
Read More...

IGM Biosciences Appoints Wayne Godfrey, M.D., as Vice President, Clinical Development

Pioneer in Cancer Immunotherapy Research and Clinical Lead for Kite/Gilead ZUMA-5 Program, Dr. Godfrey Joins...
Read More...

IGM Biosciences Appoints Julie Hambleton, M.D., to Board of Directors

Dr. Hambleton Brings More Than 25 Years of Industry and Academic Experience MOUNTAIN VIEW, Calif.,...
Read More...

IGM Biosciences Appoints Daniel S. Chen, M.D., Ph.D., as Chief Medical Officer; Names William Strohl, Ph.D., to Board of Directors

Dr. Daniel Chen, Former Global Head of Cancer Immunotherapy Development at Genentech/Roche and Noted Immuno-Oncology...
Read More...

Multimeric Anti-DR5 IgM antibody displays potent cytotoxicity in vitro and promotes tumor regression in vivo

Read More...

High Avidity Anti-CD20 IgM Antibody for Enhanced Complement-Dependent Cell Killing of Low CD20 Expressing Tumor Cells

Read More...

IGM-55.5, a novel monoclonal human recombinant IgM antibody with potent activity against B cell leukemia and lymphoma

Read More...